UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 4, 2021

AVALON GLOBOCARE CORP.
(Exact name of registrant as specified in its charter)

(Exact name of registrant as specified in its charter)				
	Delaware	001-38728	47-1685128	
	(State or Other Jurisdiction	(Commission File Number)	(IRS Employer	
	of Incorporation)		Identification Number)	
	44	400 Route 9 South, Suite 3100, Freehold, New Jersey 07728 (Address of principal executive offices) (zip code)		
		646-762-4517 (Registrant's telephone number, including area code)		
	the appropriate box below if the Form 8-K filing is in al Instruction A.2. below):	ntended to simultaneously satisfy the filing obligation of the regis	strant under any of the following provisions (see	
	Written communications pursuant to Rule 425 under	r the Securities Act (17 CFR 230.425)		
	Soliciting material pursuant to Rule 14a-12 under the	e Exchange Act (17 CFR 240.14a-12)		
	Pre-commencement communications pursuant to Ru	ale 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))		
	Pre-commencement communications pursuant to Ru	ale 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))		
Secur	ities registered pursuant to Section 12(b) of the Act:			
			Name of each exchange on	
	Title of each class	Trading Symbols	which registered	
	Common Stock, \$0.0001 par value per share	AVCO	The Nasdaq Capital Market	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).				
			⊠ Emerging growth company	
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.				

Item 1.01. Entry Into a Material Definitive Agreement.

Item 2.03. Creation of a Direct Financing Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

As of November 4, 2021, Avalon GloboCare Corp. (the "Company") (the "Company") drew down an additional aggregate of \$1,000,000 from its credit facility under that certain credit line agreement with Wenzhao "Daniel" Lu (the "Lender"), a significant shareholder and director of the Company, which provides the Company with a \$20 million line of credit (together with related documentation, the "Line of Credit"). The draw down aggregating \$1,000,000 is intended to provide working capital for the Company to use on a temporary basis for certain obligations in connection with the Company's business. As a result of these draw downs, the Company has approximately \$15.3 million remaining available under the Line Credit. This draw down increased the total principal amount outstanding under the Credit Line to \$4.7 million.

Item 9.01 Financial Statements and Exhibits

10.1 Revolving Line of Credit Agreement, dated as of August 29, 2019, between Avalon GloboCare Corp. and Wenzhao "Daniel" Lu dated August 29, 2019 (1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) (1) Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 3, 2019.	Exhibit No.		Description of Exhibit		
	10	.1	Revolving Line of Credit Agreement, dated as of August 29, 2019, between Avalon GloboCare Corp. and Wenzhao "Daniel" Lu dated August 29, 2019 (1)		
(1) Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 3, 2019.	10	4	Cover Page Interactive Data File (embedded within the Inline XBRL document)		
	(1) Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 3, 2019.				

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVALON GLOBOCARE CORP.

Date: November 9, 2021

By: /s/ Luisa Ingargiola
Name: Luisa Ingargiola
Title: Chief Financial Officer

2